Gene expression in Mon-Mac-6 cells treated with METTL3 PROTAC, WD6305 and inhibitor, UZH2

N6-methyladenosine (m6A) methylation is the most prevalent RNA modification, which plays a critical role in various bioprocesses.1 This modification is predominantly catalyzed by the m6A methyltransferase complex (MTC), consisting of core subunits such as methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14), along with cofactors like Wilms tumor 1-associated protein (WTAP). We described the development of a first-in-class potent and selective METTL3-targeted degrader, WD6305, which can effectively degrade both METTL3 and its partner protein METTL14. WD6305 showed superior antiproliferative effects in multiple AML cell lines compared to its parent inhibitor, UZH2. Here, we want to compare the changes in genes between the two. Overall design: In order to detect the gene expresion changes of Mon-Mac-6 after treatment with WD6305 and UZH2, we sequenced Mon-Mac-6 cells after treatment with 500nM DMSO, WD6305, and UZH2 for 48h.